WO2012092708A1 - 一种测定抗ra33抗体igg的方法及试剂装置 - Google Patents
一种测定抗ra33抗体igg的方法及试剂装置 Download PDFInfo
- Publication number
- WO2012092708A1 WO2012092708A1 PCT/CN2011/070028 CN2011070028W WO2012092708A1 WO 2012092708 A1 WO2012092708 A1 WO 2012092708A1 CN 2011070028 W CN2011070028 W CN 2011070028W WO 2012092708 A1 WO2012092708 A1 WO 2012092708A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reagent
- antibody
- instrument
- sample
- hole
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 171
- 238000000034 method Methods 0.000 title claims abstract description 48
- 238000001514 detection method Methods 0.000 claims abstract description 75
- 238000004458 analytical method Methods 0.000 claims abstract description 37
- 239000000758 substrate Substances 0.000 claims abstract description 20
- 238000002965 ELISA Methods 0.000 claims abstract description 17
- 238000012360 testing method Methods 0.000 claims description 57
- 239000000523 sample Substances 0.000 claims description 52
- 239000000243 solution Substances 0.000 claims description 32
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 238000005406 washing Methods 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 25
- 239000012895 dilution Substances 0.000 claims description 22
- 238000010790 dilution Methods 0.000 claims description 22
- 238000007789 sealing Methods 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 238000011049 filling Methods 0.000 claims description 11
- 238000003908 quality control method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000011148 porous material Substances 0.000 claims description 9
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 7
- 230000036046 immunoreaction Effects 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000012898 sample dilution Substances 0.000 claims description 5
- 239000012089 stop solution Substances 0.000 claims description 5
- 239000003593 chromogenic compound Substances 0.000 claims description 4
- 238000012937 correction Methods 0.000 claims description 4
- 239000000645 desinfectant Substances 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 238000007689 inspection Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000010998 test method Methods 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- 238000004164 analytical calibration Methods 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000012470 diluted sample Substances 0.000 claims description 3
- 230000009977 dual effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 102100032920 Chromobox protein homolog 2 Human genes 0.000 claims description 2
- 238000002835 absorbance Methods 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims description 2
- 238000013459 approach Methods 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 238000011010 flushing procedure Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000013026 undiluted sample Substances 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 18
- 238000003018 immunoassay Methods 0.000 description 12
- 238000003119 immunoblot Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000012864 cross contamination Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 101000978703 Escherichia virus Qbeta Maturation protein A2 Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 108091026838 U1 spliceosomal RNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010237 hybrid technique Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/52—Containers specially adapted for storing or dispensing a reagent
- B01L3/527—Containers specially adapted for storing or dispensing a reagent for a plurality of reagents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/54—Labware with identification means
- B01L3/545—Labware with identification means for laboratory containers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
Definitions
- the present invention relates to a method and a reagent device for measuring an anti-M33 antibody IgG, and belongs to the field of biological detection technology.
- Rheumatoid arthritis A is the most common systemic autoimmune disease. It is mainly characterized by chronic, symmetrical, and joint-erosive synovitis. Most of the conditions are progressive. If not treated in time, about three-thirds. One patient will be disabled. Therefore, early diagnosis and early treatment are the key to treating rheumatoid arthritis.
- the American College of Rheumatology (ACR) revised the diagnostic criteria in 1987 with clinical manifestations, and rheumatoid factor F) as the only diagnostic criterion with poor specificity. Therefore, rheumatologists are committed to finding the biological markers of early diagnosis of RA, and have achieved certain results.
- Hassfeld et al first slammed the RA33 antibody, which was named as an anti-RA33 antibody because it is a specific antibody for the diagnosis of RA (rheumatoid arthritis) and reacts with a nucleic acid protein with a molecular weight of 33 kD.
- the target antigen is a 33KD nucleic acid binding protein, which is consistent with the A2 protein in hnRNP, and the antigen is derived from He cells or Ehrilich cells.
- the detection method is immunoblotting (IBT).
- anti-RA33 antibodies were found in some patients with RA, and in about 20% of patients with systemic erythematosus (SLE) and 40% to 60% of patients with mixed connective tissue disease (MCTD). But there is literature Description
- anti-M33 antibodies in SLE patients and MCTD patients often appear simultaneously with the other two autoantibodies U1-RNP and Sm antibodies, so SLE and MCTD can be excluded by simultaneously examining U 1 - NP and Sm antibodies.
- IBT immunosorbent assay
- Has sfeld et al first reported the use of the IBT method to detect anti-RA33 antibodies in the serum of RA patients.
- This method is a hybrid technique that combines high-resolution gel electrophoresis with immunochemical analysis techniques.
- Western blotting has the advantages of large analytical capacity, high sensitivity, and high specificity. It is the most commonly used method for detecting protein properties, expression and distribution, such as qualitative and quantitative detection of tissue antigens, mass determination of peptide molecules, and virus. Antibody or antigen detection, etc.
- the disadvantages are:
- reagents Up to 11 reagents can be used for quantitative determination.
- Each test reagent should be filled with a reagent bottle, and each time a reagent is used, the liquid suction nozzle needs to be replaced to be separately added to the microplate.
- the hole not only the variety of reagent bottles, but also the operation of adding reagents is extremely cumbersome. If the automatic enzyme-free analyzer is not used, all operations must be performed manually, and the automatic analyzer is expensive. , the investment is large;
- the detection reagent is open in the detection process, which easily causes cross-contamination between various reagents and affects the detection result;
- the number of items in the test item kit configuration and use are all X 96 people. If 10 items need to be tested, the reagent configuration and usage number must be 10 X 96, if only one copy The sample needs to be tested for 10 different items, and 10 X 96 parts of reagents are also required.
- the present invention proposes a new detection method and reagent device and supporting reagents.
- the method is based on alcohol-linked immunoassay technology and seeks a more compact, accurate and effective set of methods and reagents for quantitative testing to meet clinical diagnostic needs.
- the method is based on the principle of enzyme-linked immunosorbent assay to realize the immunoassay of anti-RA33 antibody I gG, and is an independent, single-person, one-time analysis method for detecting anti-RA33 antibody I gG by enzyme-linked immunosorbent assay.
- a reagent device and a matching reagent which can store various reagents required for anti-RA33 antibody I gG drunk immunoassay on an analysis device, and the related immunology can be more conveniently performed according to the use requirements of the test item. Detection provides a better basis for clinical applications.
- the invention provides a method for determining an anti-RA33 antibody IgG, which is realized by a kit consisting of an analytical reagent device and a matching reagent for collateral immunoassay, the analytical reagent device comprising a substrate having 8 holes and A handle at one end of the substrate, which is filled and aspirated by various specific reagent solutions between the pores of the reagent device by a special specific analytical instrument, so that the sample reacts with the reagent, and then the value of the solution color after the reaction is measured, and finally The detection result is obtained by processing the measured values.
- the method for determining an anti-RA33 antibody IgG is to react a test anti-M33 antibody I gG in a sample to be reacted with a recombinant M 33 antigen to form a first immune complex, the first immune complex and the first immune complex
- the enzyme-labeled second antibody is reacted to form a second immune complex, and the second complex formed by the reaction is subjected to color development comparison analysis with the chromogenic substrate to obtain the content of the anti-RA33 antibody I gG to be tested.
- the method for determining an anti-RA33 antibody I gG wherein the second antibody is a horseradish peroxidase-labeled anti-human I gG antibody.
- the present application also provides a reagent device for determining anti-RA33 antibody IgG, comprising a substrate with 8 holes, a handle at one end of the substrate, and an analytical reagent device for detecting anti-RA33 antibody I gG by enzyme-linked immunosorbent assay and corresponding The number of matching reagent calibrators, controls, and buffer wash components.
- the reagent device for measuring an anti-RA33 antibody I gG wherein a handle of a detection reagent barcode is pasted on a handle of one end of the substrate, and the value of the barcode includes a detection item code corresponding to each detection, and a detection reagent production Batch number, reagent expiration date, qualitative correction value/quantitative determination standard curve parameter, type of enzyme-linked immunoreaction, reagent and serial number of the analytical device.
- the pore site comprises a reaction well
- reaction well is flat and has high light source/light path permeability.
- the absorbance value of visible light/ultraviolet light/fluorescence approaches zero, and the pore is coated with anti-RA33 antibody.
- Recombinant M33 antigen required for I gG which is used to contain test samples and detection reagents, and to carry out enzyme-linked immunoreactivity with these samples and reagents, and is a container for detecting immune reaction and color display and detection;
- Each reagent well contains a reagent required for the detection of anti-M33 antibody IgG by enzyme-linked immunosorbent assay. After the reagent is added, the open lip of the micropore is sealed with a sealing film.
- the reagent device for determining an anti-RA33 antibody I g G wherein the reagent for clotting immunoassay contained in the reagent well comprises an immunosuppressive inhibitor/neutralization required for detecting an alcohol-linked immunoreaction of anti-RA33 antibody IgG Agent/blocker/adsorbent, enzyme conjugate solution, chromogenic substrate solution, color development stop solution, reaction enhancer/accelerator, sample dilution solution.
- the reagent device for measuring the anti-RA33 antibody I gG wherein the sample hole, the reaction well, the dilution hole and the reagent hole have a cross-sectional shape including a flat type, a V type or a U type, or a flat type, a V type and a U type Any combination.
- the method for determining an anti-RA33 antibody I gG comprising the steps of:
- the instrument can be connected to the host through the RS232 serial port, so that the results of the normal operation of the instrument can be handled by the centralized system;
- the detection further includes the following steps:
- the instrument can automatically identify the analysis device barcode and quality.
- Control bar code and calibrator bar code the selection line can be positioned in the "sample” column or the "detection" column;
- the instrument automatically runs according to the bar code information. According to the bar code, the instrument will select the corresponding set standard curve. The program first detects the calibration product to calibrate the preset curve in the instrument. Secondly, the quality control object is controlled. Detection, if the detection result is within the marked range, it means that the built-in curve is qualified, it can be used for sample detection, and finally the sample detection procedure is started; vi i i. Dilution: The filling needle will automatically take samples from the sample hole and puncture The hole sealing film automatically draws the dilution solution to dilute the sample in the dilution hole. After the action is completed, the diluted sample is filled. Description
- the needle is moved to the reagent well for a set period of time, after which the liquid is removed;
- the filling needle will draw a certain amount of washing liquid from the corresponding tank to remove the liquid after three to five washings of the reagent hole;
- Xi i i Fill the needle piercing reagent hole sealing film and take a certain amount of stop solution to the reagent hole. Read the 0D value on the 450 ship within 10 minutes. If the ⁇ is selected by the dual wavelength method, the reference wavelength is 620nm ⁇ 690nm;
- Test result When the test program runs, click the data transmission with the host, the instrument will automatically send the results of the normal work to the host for analysis by the external data processing software, and finally generate a report for easy reference;
- the assay reagent device is an independent, single-part, single-use, alcohol-linked immunoassay reagent device dedicated to a specific analytical instrument for the determination of anti-RA33 antibody IgG.
- This detection method which uses the principle of enzyme-linked immunosorbent assay, uses a specific analytical instrument, and uses a dedicated detection kit and analytical reagent device to automatically achieve qualitative/quantitative determination of anti-RA33 antibody IgG, which is a brand new , applicable, practical, efficient, and rapid detection of anti-M33 antibody IgG;
- the barcode value includes the test item code corresponding to the test, the test reagent production batch number, the reagent expiration date, the quantitative standard curve parameter, the specific enzyme-linked immunoreaction type, and the reagent. And the information such as the serial number of the analysis device cannot be changed at will, and it is strictly controlled during use. Especially when the detection reagent is used beyond the expiration date, it will be identified and prevented from being sent out, so that the accuracy of the detection can be ensured;
- the liquid applicator is filled with test reagents or samples, the operation is automated, the amount is accurate, and the accuracy and precision of the test results are high;
- Figure 1 is a schematic cross-sectional view showing an embodiment of a reagent device for measuring an anti-M33 antibody IgG according to the present application;
- Figure 2 is a plan elevational view of one embodiment of a reagent device for determining anti-M33 antibody IgG according to the present application;
- Figure 3 is a schematic cross-sectional view showing another embodiment of the reagent device for measuring anti-M33 antibody IgG according to the present application;
- Figure 4 is a top plan view showing another embodiment of the reagent device for measuring anti-M33 antibody IgG according to the present application;
- 5 and 6 are schematic cross-sectional views showing other embodiments of the reagent device for measuring an anti-RA33 antibody I gG according to the present application;
- 1 is a sample well
- 2, 3, 4, 5, 6 are reagent wells
- 7 is a reaction well
- 8 is a dilution well
- 9 is a handle
- 10 is a sealing film
- 11 is a matrix
- 90 is a label.
- Example 1 Indirect enzyme-linked immunosorbent assay, kit and reagent device for detecting anti-RA33 antibody IgG
- the invention is based on a more compact, accurate and effective method for detecting immunoassay, and the basic principle is indirect enzyme-linked immunosorbent assay.
- the recombinant RA33 antigen is adsorbed on the solid phase, and the specific antibody in the diluted human serum is bound to the antigen by incubation, and the antibody not bound to the solid phase is washed and removed, and anti-human immunity labeled with horseradish peroxidase is added. Globulin conjugates, incubated. The unbound alcohol complex was removed and the original enzyme substrate was added. The color produced is proportional to the specific antibody concentration in the test sample.
- This method mainly achieves the immunodetection of the anti-RA33 antibody I gG by an analytical reagent device for enzyme-linked immunosorbent assay and a supporting reagent.
- an analytical reagent device for enzyme-linked immunosorbent assay and a supporting reagent.
- both analytical reagent devices and reagents from specific analytical instruments can be used to quickly and accurately determine the need for clinical diagnosis.
- the specific structure of the analysis device is as follows:
- FIG. 1-6 it is a reagent device for measuring anti-M33 antibody I gG conjugate immunoassay according to the application of the present invention, comprising a substrate 11 having 1 to 8 holes on the substrate 11 (1, 2, 3, 4, 5, 6, 7, 8), where the hole 1 is the sample hole for the sample to be tested, and the bottom surface is the bottom of the "V" groove, and the remaining holes are the reaction a hole 7, a dilution hole 8, and a reagent hole (2, 3, 4, 5, 6), the reaction hole 7 is a reaction hole for receiving a detection sample and a detection reagent and serving as a container for enzyme-linked immunoreactivity and colorimetry.
- the reaction well is a light source/optical passage through hole, and a handle 9 is provided at one end of the base body, and a label 90 for detecting an anti-RA33 antibody I gG reagent information barcode is attached to the handle.
- the reference numerals 2, 3, 4, 5, and 6 are reagent holes, and in use, the labels 2, 3, 4, 5, and 6 are filled with reagents required for detection, and The open mouth can be square or round, and the bottom surface is a "V" groove bottom. After filling the reagent or vacant, the sealing film 10 is sealed.
- the label 8 is a dilution hole for the dilution of the sample. Cover the sealing film.
- kits outside the analytical reagent device include: Calibrators, Controls, Buffer Wash, Wash, Disinfectant, and Distilled or Deionized Water.
- Example 2 Preparation of Reagent Device or Kit An indirect method for detecting anti-RA33 antibody IgG. Hole 1 is used as a container for sample to be tested, and a liquid sample is added during use for use in the detection; hole 2 is used as a hole. Sealed with a sealing film for testing and standby;
- hole position 3 as the reagent container, add the sample dilution reagent, and seal it with a sealing film for use in the test;
- the pore position 6 is used as a reagent container, and the ruthenium reaction substrate reagent is added, and then sealed with a sealing film for use in detecting;
- the recombinant RA 33 antigen has been coated, and the liquid sample, the detection reagent and the washing liquid to be tested are added as a reaction container, and finally the sleeping reaction bottom is added. Absorbance measurement after incubation;
- Use hole 8 as the sample dilution container for dilution of the sample
- a barcode 90 for anti-RA33 antibody IgG detection reagent and analysis device information is attached to the handle 9, and the barcode includes a detection item code, a detection reagent production batch number, a reagent expiration date, a qualitative correction coefficient/quantitative detection correction coefficient, an enzyme-linked immunoreaction type, and a reagent. And the serial number of the analysis device.
- a plurality of analytical devices are prepared according to the above method, and corresponding reagents are prepared, including calibrators, controls, buffered washings, washing solutions, disinfecting solutions, and distilled or deionized water. This constitutes the complete anti-RA33 antibody IgG assay kit component.
- the reagent device for detecting the anti-RA33 antibody IgG and the supporting component are loaded into the outer packaging box of the kit to prepare an anti-M33 antibody IgG kit.
- the fully automatic analyzer includes an analysis device tray that is matched to the shape of the analysis device. A total of 30 positions are available for the analysis device to be used for inspection and analysis. It also includes a modular integrated mechanical electronics structure for automated sample loading, dilution, incubation, washing and reading. Each position is independently quantified and more than 200 electronic sensors are monitored to ensure the accuracy of the results. Once the instrument is running, the analyzer tray will rotate to a different location for loading, dilution, incubation, washing, and reading steps.
- the instrument switch When the instrument switch is turned on, the instrument automatically performs a series of checks to prepare the instrument for proper operation.
- the instrument After powering up, the instrument will start a heating program to adjust the temperature to the temperature to be tested.
- the instrument can be connected to the host through the RS232 serial port, so that the results obtained by the normal operation of the instrument are handled by the centralized system.
- the instrument can automatically identify the analysis device barcode and quality.
- Control bar code and calibrator bar code the selection line can be positioned in the "sample” column or the "detection" column;
- the instrument automatically runs according to the bar code information. According to the bar code, the instrument will select the corresponding set standard curve. The program first detects the calibration product to calibrate the preset curve in the instrument. Secondly, the quality control object is detected. If the test result is within the marked range, it means that the built-in curve is qualified and can be used for sample detection; finally, the sample test procedure is started;
- Dilution The filling needle will automatically take the sample from the sample hole 1 and puncture the hole sealing film 10, and automatically draw the diluent in the dilution hole 8 for sample dilution. After the action is completed, the diluted sample will be filled with the needle. Reacting to reagent well 3 for a set period of time, after which the liquid is removed;
- washing The filling needle will take a certain amount of washing liquid from the corresponding liquid tank, and remove the liquid after three to five washings of the reagent hole 3;
- the sealing film absorbs a certain amount of horseradish peroxidase-labeled anti-human I gG antibody to the reagent well 3 to carry out a reaction, and removes the liquid after a set period of time;
- the washing cycle must be started before the instrument is turned off. This will prevent the residual salt from the solution from crystallizing in the liquid path, avoiding damage to the instrument or causing the detection of crusting to be invalid. After the washing is completed, the instrument power is automatically turned off.
- Example 4 Detection and application of patient samples, analysis of results and quality control of detection
- Example 3 Using the procedure and procedure of Example 3, the method of use can be used to quantify the level of anti-M33 antibody IgG in human serum using the kit described in Example 2.
- the anti-RA33 antibody alone is considered a marker for rheumatoid arthritis (UA), but its diagnostic sensitivity depends on the population tested.
- Anti-RA 33 antibodies do not depend on rheumatoid factor (RF), and their occurrence in RF-negative rheumatoid arthritis is about 45%, which is significant for the early diagnosis of RA.
- Anti-RA 33 antibodies are present in 70% of SLE patients with erosive arthritis (EA), so anti-RA 33 antibodies can be used as predictors of EA development in SLE. Therefore, we can conduct clinical diagnosis based on the results of the test, and initially determine the patient's condition. The final diagnosis should be considered in combination with clinical manifestations or other diagnostic methods/indicators.
- Normal reference value 0 ⁇ 25AU/mL; A certain number (statistically significant) of negative samples were detected, and the mean value of the results plus 3 standard deviations (ie +3SD) was the upper limit of the normal reference value. It is recommended that each laboratory establish its own range of normal reference values based on actual conditions.
- sample value > 30 AU/mL it indicates that the antibody concentration is significantly increased. It should be diagnosed with rheumatoid arthritis and erosive arthritis in combination with clinical manifestations or other diagnostic methods/indicators; sample value ⁇ 20 AU/ In mL, it indicates that the body anti-RA33 antibody IgG level did not increase significantly; 20 AU / mL sample value ⁇ 30 AU / mL, should be re-tested, if still suspicious, re-collected samples after 2 - 3 weeks.
- the detection of the anti-RA33 antibody I gG of a plurality of samples can be simultaneously and fully automated through the same analysis process, which makes the detection more tubular, lower in cost, shorter in detection time, less prone to cross-contamination, and easy to perform detection. And the detection has strong specificity, high sensitivity and good accuracy.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Clinical Laboratory Science (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2011/070028 WO2012092708A1 (zh) | 2011-01-04 | 2011-01-04 | 一种测定抗ra33抗体igg的方法及试剂装置 |
US13/978,233 US20130316381A1 (en) | 2011-01-04 | 2011-01-04 | Method and reagent device for determining anti-ra33 antibody igg |
CN201180063617.2A CN103384826B (zh) | 2011-01-04 | 2011-01-04 | 一种测定抗RA33抗体IgG的方法及试剂装置 |
DE112011104669T DE112011104669T5 (de) | 2011-01-04 | 2011-01-04 | Ein Verfahren und eine Reagenzienvorrichtung zur Bestimmung des Antikörpers IgG gegen RA33 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2011/070028 WO2012092708A1 (zh) | 2011-01-04 | 2011-01-04 | 一种测定抗ra33抗体igg的方法及试剂装置 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012092708A1 true WO2012092708A1 (zh) | 2012-07-12 |
Family
ID=46457180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/070028 WO2012092708A1 (zh) | 2011-01-04 | 2011-01-04 | 一种测定抗ra33抗体igg的方法及试剂装置 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20130316381A1 (zh) |
CN (1) | CN103384826B (zh) |
DE (1) | DE112011104669T5 (zh) |
WO (1) | WO2012092708A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106404757A (zh) * | 2016-06-30 | 2017-02-15 | 深圳市亚辉龙生物科技股份有限公司 | 一种抗RA33抗体IgG化学发光免疫检测试剂盒及其制备方法 |
CN109669041A (zh) * | 2019-02-02 | 2019-04-23 | 上海微银生物技术有限公司 | 一种酶免疫检测板条、酶免疫检测板及其检测方法 |
CN112730859A (zh) * | 2019-10-28 | 2021-04-30 | 东方伊诺(苏州)医疗科技有限公司 | 一种自动酶联免疫分析仪 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110514648A (zh) * | 2018-05-21 | 2019-11-29 | 博阳生物科技(上海)有限公司 | 一种化学发光分析poct检测装置及其应用 |
CN109030818A (zh) * | 2018-07-26 | 2018-12-18 | 上海微银生物技术有限公司 | 一种酶免疫检测板及其检测方法 |
CN111289759B (zh) * | 2020-03-10 | 2023-10-27 | 苏州翊讯生物科技有限公司 | Saa检测试剂盒及saa定量检测的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5053715A (en) | 1986-04-04 | 1991-10-01 | Mitutoyo Corporation | Capacitance-type measuring device for absolute measurement of positions |
CN201611346U (zh) * | 2009-09-17 | 2010-10-20 | 深圳市亚辉龙生物科技有限公司 | 一种用于酶联免疫检测的分析装置 |
CN201689095U (zh) * | 2010-01-04 | 2010-12-29 | 深圳市亚辉龙生物科技有限公司 | 一种全自动自身抗体分析仪 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE140538T1 (de) * | 1992-03-05 | 1996-08-15 | Univ Dublin | Vorrichtung zum antigennachweis |
EP1291654B1 (en) * | 2000-04-28 | 2006-11-22 | Mitsubishi Kagaku Iatron, Inc. | Automatic measuring cartridge and measuring method using it |
CN2554176Y (zh) * | 2002-07-01 | 2003-06-04 | 西安联尔生物技术有限公司 | 一种对风湿性疾病指标进行检测的生物芯片 |
-
2011
- 2011-01-04 DE DE112011104669T patent/DE112011104669T5/de not_active Ceased
- 2011-01-04 US US13/978,233 patent/US20130316381A1/en not_active Abandoned
- 2011-01-04 CN CN201180063617.2A patent/CN103384826B/zh active Active
- 2011-01-04 WO PCT/CN2011/070028 patent/WO2012092708A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5053715A (en) | 1986-04-04 | 1991-10-01 | Mitutoyo Corporation | Capacitance-type measuring device for absolute measurement of positions |
CN201611346U (zh) * | 2009-09-17 | 2010-10-20 | 深圳市亚辉龙生物科技有限公司 | 一种用于酶联免疫检测的分析装置 |
CN201689095U (zh) * | 2010-01-04 | 2010-12-29 | 深圳市亚辉龙生物科技有限公司 | 一种全自动自身抗体分析仪 |
Non-Patent Citations (1)
Title |
---|
JI CHUNMEI: "USE OF ANTI - CYCLIC CITRULLINATED PEPTIDE AND ANTI - RA33 ANTIBODIES IN DIAGNOSING RHEUMATOID ARTHRITIS", MEDICAL LABORATORY SCIENCE AND CLINICS, vol. 19, no. 3, 2008, pages 84 - 85, XP008163206 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106404757A (zh) * | 2016-06-30 | 2017-02-15 | 深圳市亚辉龙生物科技股份有限公司 | 一种抗RA33抗体IgG化学发光免疫检测试剂盒及其制备方法 |
CN109669041A (zh) * | 2019-02-02 | 2019-04-23 | 上海微银生物技术有限公司 | 一种酶免疫检测板条、酶免疫检测板及其检测方法 |
CN112730859A (zh) * | 2019-10-28 | 2021-04-30 | 东方伊诺(苏州)医疗科技有限公司 | 一种自动酶联免疫分析仪 |
Also Published As
Publication number | Publication date |
---|---|
DE112011104669T5 (de) | 2013-10-10 |
CN103384826B (zh) | 2015-11-25 |
US20130316381A1 (en) | 2013-11-28 |
CN103384826A (zh) | 2013-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102147409B (zh) | 一种测定抗核小体抗体IgG的方法及试剂装置 | |
WO2012092708A1 (zh) | 一种测定抗ra33抗体igg的方法及试剂装置 | |
CN102147408A (zh) | 一种测定抗SmD1抗体IgG的方法及试剂装置 | |
CN106226526A (zh) | 一种锌转运蛋白8抗体化学发光免疫检测试剂盒及其制备方法 | |
CN110850097A (zh) | 钙卫蛋白检测试剂盒及检测方法 | |
CN105954509A (zh) | 肾素化学发光免疫检测试剂盒及其制备方法 | |
AU2005303881A1 (en) | Device for carrying out an individual immunoassay in a fully automatic manner | |
CN106645689A (zh) | 一种促甲状腺激素受体抗体化学发光免疫测定试剂盒及其制备方法 | |
CN102147412A (zh) | 一种测定抗蛋白酶3抗体IgG的方法及试剂装置 | |
CN110687285B (zh) | 诊断试剂盒及mak16在制备系统性红斑狼疮早期诊断试剂中的应用 | |
CN106596524A (zh) | 一种胰岛素抗体化学发光免疫检测试剂盒及其制备方法 | |
CN106198958A (zh) | 抗精子抗体化学发光免疫检测试剂盒及其制备方法 | |
CN105929151A (zh) | 前列腺特异性抗原同源异构体化学发光免疫检测试剂盒及其制备方法 | |
EP2689248A1 (en) | Method for performing a rapid test | |
CN103185800A (zh) | 一种检测抗环瓜氨酸多肽抗体的试剂装置及其方法 | |
CN103185788A (zh) | 一种检测类风湿因子的试剂装置及其方法 | |
CN107102133A (zh) | 一种胰岛细胞抗体化学发光免疫检测试剂盒及其制备方法 | |
CN103185795A (zh) | 一种检测eb病毒抗体的试剂装置及其方法 | |
JPH02154679A (ja) | 医療用検査容器 | |
CN106018830A (zh) | 层粘连蛋白化学发光免疫检测试剂盒及其制备方法 | |
CN106053836A (zh) | 抗子宫内膜抗体化学发光免疫检测试剂盒及其制备方法 | |
JP2008145181A (ja) | パルボウイルスb19の検出法 | |
CN106771209A (zh) | 一种类风湿因子化学发光免疫检测试剂盒及其制备方法 | |
KIT | Human C3a | |
CN106645695A (zh) | 抗透明带抗体化学发光免疫检测试剂盒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2011712449 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11712449 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1120111046693 Country of ref document: DE Ref document number: 112011104669 Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13978233 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11712449 Country of ref document: EP Kind code of ref document: A1 |